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Abstract
Background: Alzheimer’s disease (AD) and a host of other
neurodegenerative central nervous system (CNS) proteinopathies
are characterized by the accumulation of misfolded protein aggre-
gates. Simplistically, these aggregates can be divided into
smaller, soluble, oligomeric and larger, less-soluble or insoluble,
fibrillar forms. Perhaps the major ongoing debate in the
neurodegenerative disease field is whether the smaller oligomeric
or larger fibrillar aggregates are the primary neurotoxin. Herein, we
propose an integrative hypothesis that provides new insights into
how a variety of misfolded protein aggregates can result in
neurodegeneration.
Results: We introduce the concept that a wide range of highly
stable misfolded protein aggregates in AD and other neuro-
degenerative proteinopathies are recognized as non-self and
chronically activate the innate immune system. This pro-inflam-
matory state leads to physiological senescence of CNS cells.
Once CNS cells undergo physiological senescence, they secrete
a variety of pro-inflammatory molecules. Thus, the senescence of
cells, which was initially triggered by inflammatory stimuli,
becomes a self-reinforcing stimulus for further inflammation and
senescence. Ultimately, senescent CNS cells become functionally
impaired and eventually die, and this neurodegeneration leads to
brain organ failure.
Conclusions: This integrative hypothesis, which we will refer to
as the proteinopathy-induced senescent cell hypothesis of AD
and other neurodegenerative diseases, links CNS proteino-
pathies to inflammation, physiological senescence, cellular dys-
function, and ultimately neurodegeneration. Future studies
characterizing the senescent phenotype of CNS cells in AD and
other neurodegenerative diseases will test the validity of this
hypothesis. The implications of CNS senescence as a contribut-
ing factor to the neurodegenerative cascade and its implications
for therapy are discussed.
Genetic, pathological, biochemical, animal and cell modeling
studies provide strong support for the general hypothesis that
accumulation of misfolded, aggregated proteins in the brain
triggers a complex series of events that result in neuronal
degeneration [1-4]. In Alzheimer’s disease (AD) aggregation
and accumulation of the amyloid β (Aβ) protein and
microtubule associated protein tau (MAPT) have both been
implicated as key pathogenic ‘triggers’ [5]. Aβ accumulates in
senile plaques, cerebral vessels, and, to a more limited extent,
within neurons [6]. Tau accumulates inside cells as neuro-
fibrillary tangles and tau neurites [7]. In genetic forms of AD
the data overwhelmingly support the ‘Aβ aggregate/amyloid
cascade’ hypothesis, which posits that Aβ aggregation and
accumulation precedes, and therefore drives, tau accumu-
lation [3]. In ‘sporadic’ cases it is also possible that the two
pathologies may arise, at least in part, through independent
pathways [8]. Like familial AD, mutations in a number of
genes result in accumulation of protein aggregates (for
example, ABri, ADan, superoxide dismutase, α-synuclein,
huntingtin, ataxins, and neuroserpin), triggering the patho-
logical cascade that leads to many phenotypically distinct
neurodegenerative diseases [1-3,9,10].
Herein, we will refer to the generic concept of misfolded
protein aggregation and accumulation as a proteinopathy.
Although there is reasonable consensus in the field regarding
proteinopathies as ‘triggers’ of neurodegeneration, there is
little consensus regarding the mechanisms that lead to
neuronal demise. Using the Aβ and tau proteinopathies in AD
as examples, we will present an integrated hypothesis of how
central nervous system (CNS) proteinopathies cause neuro-
degeneration through a cascade initially involving innate
immune activation, inflammation, induction of senescence,
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and subsequent neurodegeneration. We will refer to this
integrated hypothesis as the proteinopathy-induced senes-
cent cell hypothesis of neurodegeneration (Figure 1). Along
with a detailed presentation of the hypothesis and current
experimental data that support this hypothesis, we will outline
the experimental steps needed to validate this hypothesis and
explore its potential significance with respect to therapeutic
development for AD and other neurodegenerative protein-
opathies.
Step 1: misfolding and aggregation of
proteins into pathogen associated molecular
patterns
Aβ, tau and other protein aggregates in neurodegenerative
diseases are almost always found in an abnormal structural
conformation compared to the non-aggregated protein [1-4].
Many aggregates show the characteristic features of amyloid
and accumulate in an ‘abnormal’ fibrillar β-pleated sheet
structure [11]. A common theme of genetic alterations that
cause AD is that they increase the likelihood that Aβ will
aggregate into amyloid [6]. Mutations in tau that cause frontal
temporal dementia with parkinsonism linked to chromosome
17 (FTDP-17 MAPT) also alter tau in a way that increases its
likelihood to aggregate into amyloid-like structures [12-14].
Furthermore, there is evidence that mutations in, or over-
expression of, other proteins linked to neurodegeneration
enhance the likelihood that they are assembled into misfolded
aggregates, and many of these aggregates also have
characteristic features of amyloid [1-4].
When a normal protein misfolds and aggregates, it no longer
resembles a self protein; thus, it is subject to recognition by
the immune system. Misfolded self protein aggregates
resemble pathogen-associated molecular patterns (PAMPs)
and thymus independent type 2 (TI-2) antigens [15-18].
PAMPs are a group of molecules that are capable of
activating a wide array of innate immune defenses. They can
be proteins, polysaccharides, or nucleotides and are charac-
Figure 1
Proteinopathy-induced neuronal senescence. A schematic of proteinopathy-induced neuronal senescence depicts protein misfolding and
aggregation as a trigger for a self-reinforcing cycle of pro-inflammatory signals and senescence. As a critical mass of neurons acquire a
physiologically senescent phenotype overt neurodegeneration and failures in the brain’s cognitive and regulatory functions become clinically
apparent.
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Mutation Over Expression Ineffective Removal Timeterized by a repetitive molecular motif that is recognized as
non-self and can bind and activate evolutionarily conserved
pattern recognition receptors (PRRs) that initiate innate
immune signaling. Classic PAMPs are bacterial lipopoly-
saccharide, flagellin, peptidoglycan, some viruses and virus-
like particles, and double-stranded RNA. TI-2 antigens are
similar polymeric molecules that directly stimulate B cells to
secrete IgM by crosslinking of plasma membrane immuno-
globulin. Despite their chemical diversity, the unifying features
of both PAMPs and TI-2 antigens are that they are large in
size (typically greater then 100 kDa and often much larger),
and have repetitive epitopes (and at least for TI-2 antigens
require rigid presentation of the epitope with a two-
dimensional spacing of 5 to 10 nm), poor in vivo degrada-
bility, and the ability to activate complement [18]. Notably,
these features of PAMPS and TI-2 antigens are quite
reminiscent of the features of amyloid deposits [11].
Misfolded protein aggregates can theoretically activate the
adaptive immune system. However, the key step in activation
of adaptive immunity, major histocompatibility complex (MHC)
presentation of non-self peptides, is likely to limit such
activation [19]. MHC binds small peptides that are typically
cleaved from a larger protein [20]. Unless a small peptide
derived from the protein aggregate retains an abnormal ‘non-
self’ configuration following disaggregation, proteolytic
cleavage, and binding to the MHC, it will not be a strong
activator of the adaptive immune system [21]. Moreover,
classic MHC molecules are typically expressed at low levels
in the CNS and though there clearly is continuous surveil-
lance of the CNS by T cells, the low levels of T cells and
limited MHC expression are likely to limit adaptive immune
responses to misfolded self proteins in the CNS. Thus,
misfolded self protein aggregates are not likely to strongly
activate the adaptive immune response. Instead, the
proteinopathy will largely activate the innate immune system.
The recent description of proteins that can exist as functional
amyloid-like structures within select organelles challenges, to
some degree, the notion that all aggregated misfolded proteins
are PAMPs. Examples of physiologically ‘functional’ mammalian
amyloids are currently limited to amyloid formation by select
peptide hormones in secretory granules of the pituitary, amyloid
present in semen, and Pmel17 in melanocytes [22-24].
Notably, both the secretory granule amyloid and Pmel17
amyloid are contained within intracellular vesicles that most
likely sequester them from interaction with PRRs and other
forms of innate immune surveillance. Furthermore, because the
peptide hormone amyloids must dissociate in order for them to
be active, they are distinct from many pathological amyloids
and PAMPs, which are highly stable structures.
Step 2: proteinopathy-mediated activation of
innate immunity results in chronic inflammation
Amyloid or amyloid-like protein aggregates are highly resis-
tant to degradation [11]. Perhaps the clearest illustration of
this stability is seen in both in vivo imaging studies in Aβ
protein precursor transgenic mice and cross-sectional
pathology studies in inducible Aβ protein precursor trans-
genic mice [25-28]. These studies demonstrate that the
amyloid deposits, once formed, are incredibly stable even in
the absence of ongoing Aβ production. Though intracellular
aggregates, such as those found in the polyglutamine
diseases, can in certain circumstances be cleared in mice in
which the transgene is turned off entirely, this situation is not
replicated in the human disease and attempts to clear the
aggregates may result in direct impairment of the protein
quality control machinery [29-32]. Significantly, amyloid or
amyloid-like protein aggregates catalyze the structural
conversion of the normally folded protein into additional
aggregates via a seeded nucleation-dependent process.
Thus, following nucleation, the ongoing production of a
‘normal’ precursor drives additional amyloid formation
[33,34]. In contrast to amyloid, the stability and ‘seeding’ or
nucleating potential of other potentially pathogenic oligomeric
structures formed by misfolded proteins has not been studied
in detail [35,36].
We postulate that extracellular and intracellular protein
aggregates act like PAMPs and result in chronic activation of
the innate immune systems through PRRs. The concept that
misfolded protein aggregates are PAMPs and activate innate
immunity has been previously suggested by a number of
groups and is supported by a plethora of experimental data
[37-39]. Amyloid and amyloid like aggregates regardless of
their peptide or protein subunit can be shown to bind and
activate a whole array of PRRs, including Toll-like receptors,
formyl peptide receptors, receptor for advanced glycation
end products, scavenger receptors, complement and
pentraxins [37-39]. Oligomeric assemblies of amyloidogenic
proteins have not been studied as intensively with respect to
PRR activation, but in the cases that they have they can be
shown to elicit effects similar to amyloid fibrils (reviewed in
[37]). Structurally, it is likely that oligomeric proteins resemble
viruses or virus-like particles, which are known to function as
PAMPs [40].
Most of the experiments that have established amyloid,
amyloid like structures, and oligomers as PAMPs have
involved direct application of these aggregates to cells in
culture [37]. Such studies are complemented by histo-
pathological studies that show co-localization of inflammatory
cells and mediators with amyloid plaques and in vivo studies
using multiphoton imaging that show the rapid mobilization of
microglia to newly formed plaques [38,39,41-43]. These
studies strongly support the concept that extracellular
proteinopathies activate PRRs. Less well supported by direct
experimental data is the notion that an intracellular protein
aggregate acts like a PAMP, resulting in activation of PRRs
and mobilization of the innate immune defenses. Neverthe-
less, a number of pathological features seen in intracellular
proteinopathy-induced neurodegeneration suggest that these
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system. For example, binding to heat shock proteins,
induction of autophagy and binding to intracellular PRRs can
all activate the innate immune system [37,44-46].
The notion that intracellular proteinopathies activate innate
immunity incorporates and extends some aspects of the
danger theory of immune activation. This theory postulates
that an intracellular stress or pathogen results in the cell
generating a ‘danger’ signal that activates the immune system
[47]. In this case we postulate that an intracellular protein
aggregate causes the neuron or other CNS cell to send out
‘danger signals’ that activate the innate immune system. Such
‘danger signaling’ might explain the observation that
inflammatory markers are often the earliest sign of pathology
in experimental models of neurodegenerative proteinopathies
[38,48-51]. Ultimately, intracellular or extracellular, stable
protein aggregates acting as PAMPs will produce a chronic
inflammatory condition.
A major ongoing debate in the AD and the larger neuro-
degenerative disease field is whether small soluble aggre-
gates or larger, less soluble aggregates are the principle toxic
species [52-55]. In the context of this hypothesis, both small
soluble aggregates - oligomers - and larger aggregates -
fibrils - will function as PAMPs. Depending on their
concentration, location, and degradability, their ability to
activate PRRs will likely vary. Significantly, the activation of
PRRs by PAMPs elicits a response that is designed to result
in clearance or sequestration and inactivation of the PAMP. In
addition to a whole host of other variables, differential
activation of the innate immune system by different protein
aggregates and variable clearance of the aggregates
following immune activation probably contribute to the
imperfect correlations between the amounts and regional
distribution of protein aggregates with clinical and
neuropathological phenotypes [56]. Indeed, an aggregate
that elicits the strongest innate immune response may be
cleared more effectively. If this is the case, then it will always
be challenging to link the aggregate to downstream
pathology through cross-sectional analyses.
Step 3: chronic inflammation and senescence
are mutually reinforcing states
Histopathological, biochemical and molecular studies un-
ambiguously show that the AD brain is subject to a chronic
inflammatory condition [38]. The widespread gliosis and
increased levels of numerous inflammatory factors, including,
but not-limited to, chemokines, cytokines, and acute phase
reactants, in the absence of overt lymphocytic or mono-
nuclear infiltrates is consistent with inflammation resulting
from innate immune activation and not adaptive immune
responses. In AD, the inflammatory changes are noted in the
earliest stages of the disease process and have also been
shown to be early events in some of the AD mouse models of
amyloid and tau pathology. As noted above, in some cases
the earliest pathology noted is microglial activation and
increased levels of select cytokines [38,48-51]. Though often
more focal in nature, inflammation is a hallmark of other CNS
proteinopathies and is often seen as an early change in
mouse models of these diseases [57].
Recent studies have revealed a remarkable connection
between inflammatory mediators and replicative senescence
[58-64]. These studies demonstrate that a hallmark of
replicatively senescent cells is a massive increase in the
secretion of multiple pro-inflammatory proteins, including IL-6,
IL-8 (CXCL8), IL-1α and  β and monocyte chemoattractant
peptide-1 (MCP-1, CCL2) [60,63]. In certain cases it has
been shown that these secreted proteins can act in an
autocrine manner to further maintain the senescent state,
drive senescence of neighboring cells in a paracrine fashion,
and promote degenerative or proliferative changes in
neighboring cells [58,60]. It has also been shown that key
inflammatory pathways, including those mediated by IL-6 and
CXCR2 ligands, are not only upregulated by senescence but
may play a critical role in inducing and maintaining
senescence [59,62-64]. Notably IL-6 and MCP-1 are
markedly upregulated in AD, as are CXCR2 receptors
[38,65-71]. Finally, it is well-established that oxidative stress,
which almost invariably accompanies chronic inflammation,
can also induce senescence [72-74]. Oxidative stress can
also arise independently of inflammatory pathways in CNS
proteinopathies [75]. Extracellular Aβ has been reported to
directly cause oxidative stress through production of reactive
oxygen species [76,77]. Oxidative stress arising from
mitochondrial dysfunction has also been reported to be asso-
ciated with numerous neurodegenerative proteinopathies
[75]. Thus, senescence appears to be associated with an
induction of a pro-inflammatory state, but can also result from
an inflammatory state. Moreover, inflammatory mediators and
oxidative stress can synergistically act to drive senescence.
Step 4: senescence and neurodegeneration
Senescence has largely been studied in the context of dividing
cells, a phenomenon more specifically referred to as replicative
senescence. Replicative senescence was first described by
Hayflick, and the ‘Hayflick limit’ refers to the limited replicative
capacity of primary human fibroblasts or other diploid cell lines
to prolonged passaging in tissue culture [78]. Typically, such
senescence results in cells with altered morphology (large,
flattened cells with high cytoplasm to nucleus ratios), telomere
shortening or telomerase malfunction, distinct senescence-
associated hetrochromatic foci, and increased expression of a
panel of senescence-associated biomarkers (for example,
senescence-associated  β-galactosidase activity, INK4A, IL-6)
[58,60,79]. A functional definition is that a senescent cell has
lost its replicative capacity and is no longer able to respond to
growth factors. Though replicative senescence has been
postulated to be a key driver of human aging, it is more likely
that replicative senescence is simply one of many factors that
contribute to the aging process.
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neurons or even glia cells. As neurons are terminally
differentiated, it is immediately obvious that one of the critical
hallmarks of replicative senescence, inability to divide, does
not apply. Some would claim that because they are terminally
differentiated, neurons cannot senesce [80]. However, we
postulate that neurons do undergo physiological senescence
and that this senescence is accelerated in AD and other CNS
proteinopathies by inflammatory and oxidative stimuli.
Moreover, we postulate that a senescent neuron will be
defined functionally by its inability to respond appropriately to
growth factors and its expression of senescence-associated
proteins. In this scenario, other CNS cells, including glia,
neuroglial stem cells, and endothelial and smooth muscle
cells that form the cerebrovasculature, are also likely to
undergo senescent changes in response to the chronic
inflammatory environment. Senescent astrocytes might
switch from a neuroprotective phenotype to one that is less
suitable for supporting neuronal homeostasis. Senescence of
microglia cells has been proposed as a mechanism for ‘aging’
microglia, less efficient scavenger cells with diminished
phagocytic capacity and enhanced neurotoxic potential
[81,82]. Put simply, we postulate that CNS cells will display a
senescent phenotype that is physiologically similar to cells
that have undergone replicative senescence, and be func-
tionally impaired in a way that leads to neuronal dysfunction
and degeneration. Ultimately, a growing number of senescent
cells will lead to either widespread brain ‘organ failure’ as
exhibited in AD, or more or less regional brain organ failure as
seen in other neurodegenerative proteinopathies.
One of the key features of this hypothesis is that once
triggered by the proteinopathy, senescent changes are likely
to be both self-reinforcing and irreversible. In an autocrine
fashion, inflammatory mediators secreted by the senescent
neurons and glia would help to maintain the senescent state
[60]. In a paracrine fashion, senescent cells induce additional
inflammation and senescence of neighboring cells. Over long
periods of time senescent neurons become increasingly
dysfunctional and die due to a combination of diminished
response to growth factors and possible pathophysiological
effects of chronic exposure to an altered milieu of signaling
factors as well as the direct signaling effects of the protein
aggregates. Senescent changes can also affect neuronal stem
cells, leading to diminished potential for renewal of neurons.
It is likely that the senescence response is not an ‘all or none’
phenomenon. There may be a graded continuum of res-
ponses to a proteinopathy-induced stress that depends both
on the strength and acuteness of the stress as well as the
preprogrammed response of the cell. Experimental data
demonstrate that cells with high levels of anti-apoptotic
proteins often undergo senescence whereas cells with lower
levels of anti-apoptotic factors seem prone to undergo
apoptosis [83-85]. Mature neurons, which are known to
express high levels of anti-apoptotic proteins, may respond to
potentially apoptotic stresses by senescing. At least in
culture, a lower level of oxidative stress can drive senescence
whereas a higher level can drive apoptosis. The notion that
cellular ‘stress’, depending on the context, can result in two
different endpoints, either apoptosis or senescence, may help
to explain the disparate endpoints observed in various
neurodegenerative proteinopathy models. In models where
the cells are ‘primed’ to undergo apoptosis, a proteinopathy-
driven stress will more likely drive apoptosis. In models where
the proteinopathy is overwhelming, apoptosis may also be the
primary endpoint. If the proteinopathy develops more
insidiously, senescence may result.
Of course there is extensive neuronal loss in AD. So how
would a senescent cell die? Senescent cells are stable for
some period of time, and little information has been
published on how they die. As noted above, in vitro studies
suggest that senescence is an alternative pathway to
apoptosis and that senescent cells are resistant to
apoptosis. Of note, a recent study has shown that senescent
keratinocytes die by autophagic cell death, a cell death
pathway characterized by an increase in macroautophagic
activity [86]. In many neurodegenerative diseases auto-
phagic cell death has been implicated as an alternative to
apoptotic or necrotic mechanisms [45,87].
A more speculative extension of this hypothesis in AD is that
the senescent phenotype could be the key link between Aβ
proteinopathy and secondary proteinopathies that are seen in
the AD brain, including those involving tau, α-synuclein and
TDP-43. At least for tau and α-synuclein there is experimental
evidence that an Aβ proteinopathy can enhance, if not trigger,
a tauopathy or synucleinopathy. Despite intense investigation,
there is no consensus regarding the pathways that relay the
signals between Aβ and tau, synuclein, or TDP-43. Although
it is possible that we simply have not identified the single
critical factor, it is perhaps more likely that Aβ proteinopathy
induces a plethora of changes that drive the secondary
proteinopathies. Given that senescence triggers gross
changes in the transcriptome and secretome, perhaps
senescent changes mediate the secondary proteinopathy?
Future studies: how do we prove that the AD
brain is senescing?
Recent studies of the senescence-associated secretory
phenotype (SASP), also termed the senescence-messaging
secretome (SMS), have identified a number of secreted
biomarkers associated with replicative senescence [58,60,
63]. Depending on the cell type examined, the method of
induction of senescence, and the methodology used to
identify the secreted proteins, the secretome and
transcriptome that defines the SASP/SMS can be variable.
However, certain proteins are invariably identified in these
studies. Many of the proteins consistently upregulated during
senescence are inflammatory mediators, including IL-6, IL-8
and other chemokines and cytokines [58,60,63]. Though not
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biomarkers that comprise the core SASP/SMS phenotype
and secreted biomarkers of AD (Table 1). This overlap
provides evidence for a SASP/SMS in the AD brain, with
many of these features seen in mouse models of AD. At least
in AD, it has been challenging to define the nature of the
‘immune-system dysregulation’ based on pathway-type
analyses; the overlap between the SAPS/SMS and bio-
markers of AD suggest that the ‘immune-system dysregu-
lation’ may, in fact, reflect senescence [71].
Given the large number of inflammatory proteins that have
been implicated in the SASP/SMS, one of the challenges in
moving forward is to discriminate between ‘classic’ reactive
neuroinflammation and senescence in the diseased brain. If
one uses replicative senescence as a guide, the key
observations that would distinguish a senescence from an
inflammatory phenotype are: that inflammatory mediators are
expressed by cells such as neurons that do not normally
produce them; that neurons and other cells in the AD brain
exhibit cytoplasmic and nuclear markers of senescence; and
that the cells displaying these markers of senescence are
both functionally impaired and exhibit a SASP/SMS
phenotype. The links between senescence and inflammation
could also be evaluated through a number of experimental
paradigms. For example, does overexpression of inflammatory
factors, such as IL-6 in the brain, drive senescent markers in
CNS cells? Does forced expression of classic inducers of
senescence, such as P53 or INK4A, in adult neurons drive
senescence and inflammation?
Though clearly there is much work to be done to move this
hypothesis forward, there is sufficient evidence in the
literature to make the case for further study. In the AD brain
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Table 1
Senescence-associated secretory phenotype/senescence messaging secretome biomarkers in Alzheimer’s disease
Protein Alteration(s) in ADa Association with senescence 
IL-6 ↑ in B, C, P [65,71,120] ↑ in oncogene-induced senescence (OIS); mediates the SASP in vitro; 
knockdown results in senescence bypass [59,63]
IL-8 (CXCL8) and other  ↑ IL-8 in B, C, P, focal ↑ CXCR2 in B  ↑ IL-8 and other CXCR2 ligands in multiple in vitro models of 
CXCR2 ligands/CXCR2  in plaque-associated dystrophic  replicative senescence; CXCR2 signaling functionally implicated in 
neurites [66,68,69] replicative senescence [59,63,64]
MCP-1 ↑ in B [65] ↑ in vitro in multiple models of replicative senescence
IL1-α↓ in P [71],  P [121,122],  Implicated in endothelial cell senescence [124,125]
↑ mRNA in B [123]
ICAM-1 ↑ in B, P [71,126-128] ↑ in vitro in replicative senescence [63]
IGFBP ↑ IGFPB6 in P [71], ↑ IGFPB2 Various  IGFBP  ↑ in replicative senescence; IGFBP sufficient and 
and 6 in C [129] required for replicative senescence in various models [130-133]
GM-CSF  to ↑ in C [134,135] ↑ in vitro in replicative senescence [63]
Osteoprotegerin  ↑ in P [136] ↑ in vitro in replicative senescence [63]
PAI-1 CNS homolog neuroserpin ↑ in B  ↑ in vitro in models of replicative senescence and critical for induction 
[137] [138]
TGF-β↑ in B, C, P [38,139] ↑ in vitro in multiple models of replicative senescence; implicated in 
inducing replicative senescence [140,141]
WNT2 Wnt pathway implicated in  ↓ WNT2 in replicative senescence and OIS [143]
pathogenic signaling cascades in 
AD. No rigorous biomarker studies. 
Aβ implicated as blocking Wnt 
signaling [142]
sPLA2/sPLA2R ↑ group IV isoform of phospholipase  ↑ sPLA2/sPLA2R in replicative senescence; sPLA2 (PLA2G2A) can 
A(2) in B [144] induce senescence in vitro [145] 
IGF-1 Some reports indicate ↑ in AD brain  Linked to life-span extension [58,60]
[146]
MMPs Various MMPs ↑ in B and P [147] MMP3 ↑ associated with replicative senescence [148]
aB, brain; C, cerebrospinal fluid; P, plasma. Up and down arrows indicate increased and decreased levels, respectively. AD, Alzheimer’s disease;
CNS, central nervous system; GM-CSF, granulocyte-macrophage colony stimulating factor; ICAM, intracellular adhesion molecule; IGF, insulin-like
growth factor; IGFBP, insulin-like growth factor binding protein; IL = interleukin; MCP, monocyte chemoattractant peptide; MMP, matrix
metalloproteinase; OIS, oncogene-induced senescence; PAI, plasminogen activator inhibitor; sPLA2, soluble phospholipase A2; SASP,
senescence-associated secretory phenotype; sPLA2R, soluble phospholipase A2 receptor; TGF, transforming growth factor.neurons strongly stain for MCP-1 and IL-6, suggesting that
these inflammatory mediators are being ‘ectopically expressed’,
or at least dramatically upregulated, in cells that are not
professional immune cells [65]. In addition, neurons stain and
can be shown to actually express the mRNA for a number of
other secreted inflammatory proteins [37,38]. Notably, some
of the neuronal expression of inflammatory markers can be
seen in mouse models of AD and other neurodegenerative
disorders [48,88]. Cytoplasmic or nuclear protein markers
associated with senescent cells are often cell-cycle proteins,
tumor suppressors, or cell-cycle regulators [80]. In AD and
other neurodegenerative diseases there is often marked
upregulation of cyclins, p53 and related proteins, and cyclin-
dependent kinase inhibitors that have also been implicated in
the senescent phenotype (Table 2) [89-91]. Often these
markers are upregulated in tangle-bearing neurons. Notably,
there are no reports about the presence of a widely used
‘biomarker’ of senescence, senescence associated β-
galactosidase activity, in AD or any other neurodegenerative
condition [92].
Changes in telomere length, telomere activity, and the
presence of distinct heterochromatic nuclear bodies (called
senescence-associated heterochromatic foci) are also well-
established markers of replicative senescence [80,93].
However, given the terminally differentiated state of neurons,
it is unclear whether these markers would be expected to be
seen in physiological senescence of neurons in the AD brain,
or even in any of the CNS cells. For example, even
senescence-associated heterochromatic foci are typically
only seen in human cells and have been much more difficult
to demonstrate in mouse cells [94,95]. Furthermore, mouse
cells can undergo replicative senescence without shortened
telomeres [80]. Thus, it is clear that the nuclear biomarkers of
human replicative senescence may not apply to studies of
CNS senescence.
Autophagy represents an additional potential link between
senescence and neurodegeneration. Altered autophagy has
been implicated in AD and many other neurodegenerative
conditions [45,96]. Genetic removal of genes involved in
autophagy results in neurodegeneration [97,98]. More
generally, autophagy plays a key role in organismal aging and
lifespan [99,100]. Genetic alterations that induce premature
aging phenotypes are associated with autophagy induction.
Autophagosomes accumulate in senescent fibroblasts [101].
In addition, it also has been shown that autophagy is an
effector mechanism of replicative senescence [102]. It is
activated during senescence, as are a subset of autophagy-
related genes, and inhibition of autophagy delays oncogene-
induced replicative senescence [103,104]. Finally, it has
recently been postulated that autophagy is a key mechanism
in immune responses to intracellular pathogens [105].
Alternative theories
The main working hypothesis in AD and other CNS
proteinopathies has been that some species of the
aggregated misfolded protein are directly neurotoxic
[1-4,106]. There have been many variations on the theme of
the presumptive neurotoxic protein aggregate. In primary
neuronal culture systems it has been possible to reproducibly
demonstrate that a variety of protein aggregates cause some
form of ‘neurotoxicity’. For example, Aβ aggregates ranging
from oligomers (dimers, trimers, tetramers, dodecamers to 50-
to 100-mers), soluble protofibrils, actively growing fibrils, to
mature fibrils have been implicated as potential pathological
entities in AD [3,107-114]. Despite this intense focus on
finding the exact assembly that is the real ‘neurotoxin’, there is
little, if any, consensus in the field regarding this issue, in large
measure because it has been difficult to unequivocally
demonstrate that some of the proposed misfolded neurotoxins
exist in vivo. Given the considerable body of data showing that
protein aggregates can be directly neurotoxic by causing
calcium influx, altering synaptic plasticity, impairing axonal
transport and mitochondrial function, or altering other
homeostatic functions in the cell, we believe that direct
neurotoxic effects of protein aggregates probably do play
some role in AD and other neurodegenerative diseases.
However, we would argue that a slow degenerative phenotype
is hard to reconcile with a direct toxic mechanism and that if
indeed there were a ‘smoking gun’ aggregate that was directly
neurotoxic, that it would likely show a much better and more
consistent correlation with disease or disease progression
than do any of the current aggregates.
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Table 2
Cytoplasmic and nuclear protein biomarkers of senescence in Alzheimer’s disease
Protein Alteration(s) in AD Association with senescence 
p53 ↑ in neurons, astrocytes [149,150] Constitutively active p53 can induce senescence [151,152]
INK4A (p16) ↑ in neurons with NFT [153,154] Activated in senescence [155,156]
Senescence associated- Not examined Classic widely accepted biomarker of senescence [92]
β-galactosidasea
Cylcins D, E ↑ in neurons [157] ↑ in endothelial cells and fibroblasts during senescence [158,159]
aSenescence associated-β-galactosidase is β-galactosidase activity detected at pH 6.0. AD, Alzheimer’s disease; NFT, neurofibrillary tangle.Organisms have developed many ways to adapt to stressful
stimuli. In the mature nervous system a key adaptive
mechanism is to try to keep largely irreplaceable neurons
alive. One of the most remarkable examples of this is that
pathogenic viruses can be cleared from neurons by activation
of the innate and adaptive immune systems in a non-cytolytic
fashion [115]. In the periphery this immune activation would
typically result in significant collateral damage and killing of
the infected cells. As noted previously, there is some
evidence that, in response to stress, a cell can either undergo
apoptosis or senescence [104]. Given that mature neurons
have many mechanisms to protect them from apoptosis, we
might speculate that the same stress that induces apoptosis
in a primary embryonic neuronal culture may induce
senescence in the intact mature CNS.
Therapeutic implications
Replicative senescence does not appear to be easily
reversible [80]. In the few examples where replicative
senescence has been reversed in culture, the reversal
typically requires inactivation or downregulation of tumor
suppressors [116,117]. Thus, from a therapeutic point of
view, reversal of a replicatively senescent phenotype poses
serious problems as it increases the likelihood for tumori-
genesis. Indeed, it is generally thought that replicative
senescence is a mechanism designed to suppress tumori-
genesis. If cells in the AD or other neurodegenerative disease
brain are physiologically senescent, it may be very challeng-
ing to reverse the senescent phenotype. Of course, an
enhanced understanding of physiological neuronal or glial
senescence may reveal distinct differences between
replicative senescence and the physiological senescence of
these specialized cells. Understanding whether such differ-
ences are present may reveal new therapeutic approaches to
treat many neurodegenerative diseases.
Recognizing that proteinopathy-induced inflammation may
drive senescence, and thereby induce neurodegeneration,
reinforces therapeutic efforts designed to prevent the
formation of or clear the proteinopathy and also potentially
reveals new pathways that could be the focus of therapeutic
efforts. In the former case, the rationale is obvious - prevent
the proteinopathy and the downstream cascade is prevented.
Of course, as discussed in recent reviews, this type of
therapy targeting the trigger of the disease is likely to be
much more effective as primary prevention and may have little
therapeutic benefit once degeneration is entrenched [5,118].
If some aspects of the degenerative cascade downstream of
the proteinopathy are self-reinforcing and difficult to reverse,
then therapeutics aimed at the initiator of the cascade will
almost certainly have limited benefit when administered once
these downstream cascades have begun. In the latter case,
the notion that the inflammatory and senescent phenotypes
may be mutually reinforcing responses that are capable of
inducing pathological changes in a paracrine fashion
establishes a new framework for understanding the interplay
between chronic neuroinflammation and neuronal dysfunction.
Further elucidation of an inflammatory senescence network
may reveal multiple new targets for intervention. In particular,
novel anti-inflammatory approaches designed to reduce the
paracrine effects of the SASP/SMS may limit the spread of a
neurodegenerative process, and thereby limit the collateral
damage caused by a proteinopathy.
Summary: age, aging, senescence, and
neurodegeneration
The major risk factor for developing AD and other neuro-
degenerative diseases is age. Because of this association
many in the field have proposed that aging contributes to the
risk for developing AD and other neurodegenerative diseases.
Often the semantic distinction between age and aging is not
well-defined even by those who use the terms. We use the
term aging to refer to distinct biological processes that are
altered as an organism grows older, and age will simply be
used to denote time. Though it remains possible, and even
likely, that aging does contribute to the risk of developing AD
or other neurodegenerative conditions, genetic studies
indicate that aging effects can be overcome. Essentially, the
same neurodegenerative disease can be driven in a relatively
young person by a genetic alteration that accelerates the
induction of the proteinopathy. For example, when the
polyglutamine expansion is large enough, Huntington’s
disease can occur in children [119].
As alluded to previously, replicative senescence has been
implicated as a key component of the aging process. In the
context of a neurodegenerative cascade we would propose
that senescence of CNS cells is a reinforcing pathway
downstream of a proteinopathy that can, in an autocrine and
paracrine fashion, create an environment that results in aging
of the brain. Indeed, senescence appears to reinforce both
chronic inflammation and oxidative stress, two factors that are
thought to play a key role in the aging process. This might
explain why genetically driven early onset forms of AD and
other neurodegenerative diseases mimic late onset sporadic
forms of the disease.
The proteinopathy-induced senescent cell hypothesis of AD
and neurodegenerative disease that we describe here
provides a novel integrative intellectual framework for future
studies of pathological cascades in AD and other neuro-
degenerative diseases. Such studies may broaden our
understanding of the phenotype of senescing cells and also
identify novel therapeutic targets for the treatment or
prevention of AD and other neurodegenerative disorders.
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